EP0264036A2 - Dispositif analytique et méthode pour la détection de chlamydia trachomatis et neisseria gonorrhoeae - Google Patents

Dispositif analytique et méthode pour la détection de chlamydia trachomatis et neisseria gonorrhoeae Download PDF

Info

Publication number
EP0264036A2
EP0264036A2 EP87114415A EP87114415A EP0264036A2 EP 0264036 A2 EP0264036 A2 EP 0264036A2 EP 87114415 A EP87114415 A EP 87114415A EP 87114415 A EP87114415 A EP 87114415A EP 0264036 A2 EP0264036 A2 EP 0264036A2
Authority
EP
European Patent Office
Prior art keywords
antigen
particles
sample
matrix
assay
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
EP87114415A
Other languages
German (de)
English (en)
Other versions
EP0264036A3 (en
EP0264036B1 (fr
Inventor
Vincent Andrew Varitek, Jr.
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Abbott Laboratories
Original Assignee
Abbott Laboratories
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Laboratories filed Critical Abbott Laboratories
Priority to AT87114415T priority Critical patent/ATE91178T1/de
Publication of EP0264036A2 publication Critical patent/EP0264036A2/fr
Publication of EP0264036A3 publication Critical patent/EP0264036A3/en
Application granted granted Critical
Publication of EP0264036B1 publication Critical patent/EP0264036B1/fr
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/571—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses for venereal disease, e.g. syphilis, gonorrhoea
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54366—Apparatus specially adapted for solid-phase testing
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56911—Bacteria
    • G01N33/56927—Chlamydia

Definitions

  • the present invention is generally directed to a device and method for accurately detecting Chlamydia trachomatis and Neisseria gonorrhoeae antigens.
  • the detection of these two types of antigens is complicated by the difficulty in obtaining sufficient quantity of sample to test and by the low concentration of antigen present in such samples. Therefore it is desirable to design a device and method whereby minimal amounts of sample can be accurately tested and minimal amounts of the particular antigen detected.
  • One device which can be employed to identify antigens by performing a binding assay is TESTPACKTM manufactured by Abbott Laboratories, Abbott Park, Illinois and disclosed in U.S. Application Serial Nos. 784,416 filed October 4, 1985, and 831,013 filed February 18, 1986 (both herein incorporated reference).
  • the device employs an enzyme immunoassay technique and comprises a plurality of substantially spherical, solid particles immobilized within a porous fiber matrix.
  • the particles may have a substance coated on their surface which is capable of reacting with analyte present in a sample.
  • the sample is brought into contact with the porous matrix where analyte present in the sample binds to the microparticle surface where it can be detected.
  • the present invention is directed toward a solid-phase assay device useful in a binding assay to determine the presence of Chlamydia trachomatis or Neisseria gonorrhoeae antigen in a sample.
  • the solid-phase device comprises a substantially planar layer of a material having a porous matrix of fibers and characterized by a plurality of substantially spherical, solid particles comprising polytetrafluoroethylene having an average diameter of from 0.1 to 10 microns. The particles are retained and immobilized within the matrix upon the fibers.
  • the substantially planar layer has a first, sample-contacting surface and a second surface opposed to the first surface, and is disposed in the device such that, when the device is performing the assay, at least a portion of the sample contacting the first surface passes through the substantially planar layer to the second surface.
  • the polytetrafluoroethylene particles serve to bind the antigen which can then be identified by immunoenzyme technique.
  • the device can further employ on-board controls to assure accurate identification and readily recognizable results.
  • the present invention is directed toward a method for performing a binding assay to determine the presence of Chlamydia trachomatis or Neisseria gonorrhoeae antigen in a test sample.
  • the steps comprise:
  • the subject invention is directed toward a method for detecting the presence of Chlamydia trachomatis or Neisseria gonorrhoeae antigen in a fluid sample. This method comprises the steps of:
  • the bound particle complex is observed by treatment with an enzyme-conjugated antibody or antigen which is treated with an indicator substance such that the comples can be observed either visually or with instrumentation.
  • the subject invention is characterized by employing microparticles of polytetrafluorethylene to effectively bind the Chlamydia trachomatis or Neisseria gonorrhoeae antigen.
  • Polytetrafluoroethylene has been found to be superior to other microparticles. This is especially valuable because generally the samples of interest are small in quantity or low in concentration of antigen.
  • the present invention is directed toward an improved method for identifying Chlamydia trachomatis ( Chlamydia ) and Neisseria gonorrhoeae ( gonorrhoeae ) antigen present in a sample.
  • the subject device and method is adapted to detecting the presence of small quantities of Chlaymdia and gonorrhoeae antigens present in a biological fluid.
  • the device and method employ an improved form of a solid-phase immunoassay technique for performing colormetric or other enzyme immunoassay analysis of biological fluids.
  • the device as depicted in Fig. 1 shows a cross-sectioned view of the various components necessary to understanding the subject improvements.
  • the device 10 comprises a substantially planar, generally circular, disk-shaped reaction matrix 12.
  • the matrix 12 contains the special particles of the invention, as described herein, and is disposed within the device 10 such that the various chemical reactions and changes necessary to perform a binding assay can take place therein for visual or instrumental detection.
  • the matrix 12 has a sample-contacting surface 12a and a surface 12b opposed therefrom.
  • the filter matrix 12 is a "porous" filter matrix meaning that the matrix is composed of a material into which fluids can flow and easily pass through. Appropriate materials can include glass fibers, cellulose, nylon, or other fibrous materials well know in the art.
  • One perferred material is "Whatman GF/D” glass fiber filter paper (Whatman Reeve Angel, Inc., Clifton, New Jersey) which has a nominal thickness of 0.032 inch; however, thickness is not a critical factor.
  • the device 10 additionally includes a carrier 14 within which the matrix 12 is disposed.
  • the carrier 14 can be made of any suitable material such as plastic, metal or other rigid or semi-rigid substance. Especially preferred as a material for the carrier 14 is a plastic commercially known as "ABS", and available from the Monsanto Company, St. Louis, Missouri.
  • ABS plastic commercially known as "ABS”, and available from the Monsanto Company, St. Louis, Missouri.
  • the carrier 14 completely surrounds the matrix 12 and functions as a support and holder therefore.
  • the carrier 14 has a generally circular flange 16 for supporting and tightly holding the matrix 12.
  • a fluid chamber is generally defined by sidewalls formed by an outer wall surface 16a of the flange 16 and a base wall formed by the sample contacting surface 12a of the matrix 12.
  • the device 10 further comprises absorbent means 20 disposed in the carrier 14, as shown, for absorbing fluids during use of the assay device.
  • the absorbent means 20 of the device 10 can comprise one or more layers of material and is in physical contact, as shown, with the barrier material 18, when used, or with the reaction matrix 12. This especially advantageous feature enables excess fluid, during the performance of an assay using the device 10, to be easily absorbed, as necessary, after passage of such excess fluid from the reaction matrix 12 during the assay procedure.
  • the absorbent means 20 can be virtually any moisture of fluid-retaining material, e.g., that available from James River, and designated "105 point” or "50 point", or, as is especially preferred, a combination of one or more layers of each of the foregoing.
  • Barrier means is provided for restricting fluid flow in the solid phase analytical devices. This aspect is particularly advantageous when used in solid phase analytical devices having a permeable reaction surface or matrix, or filter layer, and an absorbant layer for absorbing fluids used in the device to permit the flow of fluids from the reaction surface to the absorbant means or layer while preventing the back flow of fluids from the absorbant layer to the reaction matrix.
  • the barrier means comprises a layer of barrier material 18 extending under the matrix 12 and within the carrier 14.
  • the barrier material 18 is in contact with the surface 12b of the matrix 12, and functions, when the device is in use, to restrict fluid passing through the matrix 12, to and through the surface 12b, and into the layer 18, from re-contacting the surface 12b.
  • Layer 18 is employed as a fluid restrictive layer and to help prevent or eliminate "background" interference in the matrix 12.
  • this feature is not essential or critical to the basic functions of concepts of the matrix 12, and can be omitted from the device if desired. If omitted, the device generally will perform satisfactorily in an assay, but possibly with less sensitivity (diminished detectable response).
  • the layer 18 can comprise any suitable material capable of restrictive, substantially "one-way” flow of fluid or moisture.
  • suitable materials for this purpose are polyethylene weave materials manufactured and sold by Ethyl Visqueen Corp., Baton Rouge, Louisiana under the designations "X-6057” (1.0 mil) and "X-6108" (1.25 mil) as well as those materials described in U.S. Patents 3,939,135 and 4,342,314.
  • Another suitable material is "LydairTM Grade 254" from Lydall, Inc., Manchester, Connecticut.
  • the analytical device 10 of the invention can optionally include a filtering means 22 disposed over surface 12a of the reaction matrix 12.
  • the filtering means 22 can be press-fitted into the carrier 14 by means of a retaining ring 22a, and preferably has a removable portion 22b having a handle portion 22c.
  • the means 22 is further composed, for example, of a suitable porous of fibrous material 22d such as a glass or cellulose filter membrane in a plastic surround; especially preferred are "LydairTM Grade 254" from Lydall, and "GF/F” or “GF/D” from Whatman Reeve Angel, Inc., Clifton, New Jersey, either singly or in combination.
  • an instrumental determination can also be made of a detectable response therefrom, e.g., corresponding to the reflectance of visible light, or intensity of fluorescence or the like, produced by the matrix 12 as a result of the chemical and biological reactions and changes which occur therein when an assay is performed. Accordingly, the detectable response from the device 10 can be measured by, for example, a reflectometer.
  • the subject invention can be employed by incubating the sample with a plurality of the spherical, solid particles comprising polytetrafluoroethylene. After the analyte becomes bound to the particles, the particles are contacted with a porous, fibrous matrix, whereby at least a portion of the particles become retained and immobilized within the matrix. The bound particles are then treated with an enzyme-conjugated antibody or antigen. The particles are washed to remove excess enzyme-conjugate and an indicator substance is added to produce a detectable color or other response.
  • the subject spherical, solid particles comprising polytetrafluoroethylene can be employed as the solid phase components in the methods described in U.S. Patents 4,497,899 and 4,497,900.
  • the methods and device are characterized by employing a plurality of substantially spherical, solid particles comprising polytetrafluoroethylene to bind the analyte.
  • polytetrafluoroethylene particles are TeflonTM particles, a trademark of DuPont E.I. De Nemours & Co., Wilmington, Delaware.
  • the particles are homopolymers of polytetrafluorethylene; however, derivations of polytetrafluoroethylene can also be employed.
  • the polytetrafluoroethylene particles are deposited into a fiber matrix (either before or after binding the antigen, depending upon the method employed) where they are retained and immobilized.
  • "Retained and immobilized” means that the particles, once upon the fibers of the material, are not capable of substantial movement to positions elsewhere within the material, (i.e., to other fibers), or cannot be removed completely from the material without destruction thereof. No special treatment is necessary to retain and immobilize the particles on the fiber matrix, as they have been found to readily adhere to the fibers upon exposure thereto.
  • the particles have an average individual diameter of from about 0.1 to about 10 microns more preferably from about 2 to about 5 microns in diameter and an average density of about 2.14 gm/cm3. It is to be recognized that the particles can be present as aggregates which can exceed 200 microns in diameter.
  • the particles are substantially uncoated and in fact it has been found that this is the preferred method for performing the assay for Chlamydia and gonorrhoeae antigens.
  • further embodiments can include coating the particles with antibody or other substances to assist in the binding of antigen.
  • the polytetrafluoroethylene microparticles are extremely stable under a variety of conditions and therefore can be employed with a wide range of samples containing the Chlamydia or gonorrhoeae antigens.
  • the microparticles are resistant to strong acids and bases as well as most organic solvents.
  • the microparticles are also stable from -240° to 260°C and because they are hydrophobic they absorb minimal amounts of water.
  • microparticles were compared for their ability to bind antigen in an enzyme immunoassay specific for Chlamydia .
  • Chlamydia antigens were absorbed by microparticle suspensions.
  • the bound analyte was separated from unbound analyte by centrifugation and the absorbed analyte detected using rabbit anti- Chlamydia and goat anti-rabbit globulin conjugated to horseradish peroxide to detect immune complexes.
  • the indicator employed were ortho phenylene diamine. Following color development the microparticles were removed by centrifugation and the supernatants transferred to cuvettes for measuring relative absorbance at 492 nm with a spectrophotometer.
  • the sensitivity of the polytetrafluoroethylene particles was further demonstrated by measuring the absorbancy at 492 nm when exposed to decreasing levels of microorganism.
  • a similar centrifugal enzyme immunoassay technique was employed as in Example I. The absorbancy measured at varying concentrations of Chlamydia is shown below:
  • the results indicate excellent sensitivity to as low as 50,000 organisms per millimeter with over a three-fold difference between the blank and the sample at this level.
  • the sensitivity of the polytetrafluoroethylene particles was further evaluated in the instant solid-phase device (TESTPACKTM) by immobilizing microparticles in the glass fibrous matrix to form the reaction matrix.
  • the reaction matrix was then treated with Chlamydia microorganisms at various levels of concentration and then visual colormetric change and reflectance was measured after treatment with an indicator substance.
  • the signal was measured visually on a scale of 1 to 4 for color intensity for positive results with 4 being a blue-black color and 1 being a light blue color.
  • the signal was also quantified by a reflectometer which measured percent reflectance. The perecent reflectance corresponded to the color intensity with the lowest reflectance indicating a very dark color.
  • the subject invention can also provide "on-board" control areas to simultaneously display detectable responses corresponding to a positive control (which will display a detectable response indicative of a valid assay result, regardless of the presence or absence of an analyte of interest in a test sample), and a negative control (which will display a detectable response change only if the assay results are invalid).
  • a positive control which will display a detectable response indicative of a valid assay result, regardless of the presence or absence of an analyte of interest in a test sample
  • a negative control which will display a detectable response change only if the assay results are invalid.
  • on-board negative and positive control areas 30 and 32 can be provided on the reaction surface or matrix 12 of the analytical device 10.
  • the analyte binding area 34 indicates a positive test result to the user.
  • control areas 32 and 34 are configured to provide a readily recognizable result to the user as shown in Figure 3C.
  • the negative control area 30 is formed by maintaining the area 30 free of substances which will retain the enzyme label or other signal response material during the assay.
  • the positive control area 32 is formed by providing a substance capable of binding the enzyme label or other signal response material regardless of the presence of the antigen of interest.
  • the analyte binding area 34 is formed by coating the microparticles of polytetrafluoroethylene at this position to bind the antigen of interest. In other embodiments the device can contain only the analyte binding area 34 and other configurations of areas 30, 32, and 34 can be employed.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
  • Measurement Of The Respiration, Hearing Ability, Form, And Blood Characteristics Of Living Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Manufacture Of Porous Articles, And Recovery And Treatment Of Waste Products (AREA)
  • Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
  • Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
EP87114415A 1986-10-16 1987-10-02 Dispositif analytique et méthode pour la détection de chlamydia trachomatis et neisseria gonorrhoeae Expired - Lifetime EP0264036B1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AT87114415T ATE91178T1 (de) 1986-10-16 1987-10-02 Analytisches geraet und verfahren zum nachweis von chlamydia trachomatis und neisseria gonorrhoeae.

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US91939686A 1986-10-16 1986-10-16
US919396 1986-10-16

Publications (3)

Publication Number Publication Date
EP0264036A2 true EP0264036A2 (fr) 1988-04-20
EP0264036A3 EP0264036A3 (en) 1989-08-09
EP0264036B1 EP0264036B1 (fr) 1993-06-30

Family

ID=25442004

Family Applications (1)

Application Number Title Priority Date Filing Date
EP87114415A Expired - Lifetime EP0264036B1 (fr) 1986-10-16 1987-10-02 Dispositif analytique et méthode pour la détection de chlamydia trachomatis et neisseria gonorrhoeae

Country Status (7)

Country Link
EP (1) EP0264036B1 (fr)
JP (2) JPH07104354B2 (fr)
AT (1) ATE91178T1 (fr)
AU (1) AU605185B2 (fr)
CA (1) CA1306415C (fr)
DE (1) DE3786388T2 (fr)
ES (1) ES2042526T3 (fr)

Cited By (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1989000695A1 (fr) * 1987-07-14 1989-01-26 The Victoria University Of Manchester Procede permettant le diagnostic d'infections par detection d'antigenes de lipopolysaccharide
US4818677A (en) * 1987-12-03 1989-04-04 Monoclonal Antibodies, Inc. Membrane assay using focused sample application
EP0335244A2 (fr) * 1988-03-28 1989-10-04 Abbott Laboratories Dispositif d'analyse en phase solide et procédé pour son utilisation
EP0401913A1 (fr) * 1989-06-05 1990-12-12 Janssen Pharmaceutica N.V. Dosage en phase solide à utiliser avec un développeur physique
EP0402993A2 (fr) * 1989-06-14 1990-12-19 Johnson & Johnson Clinical Diagnostics, Inc. Trousse d'essai diagnostique et procédé pour la détermination de l'antigène chlamydia utilisant une membrane ayant des groupes hydroxyles à la surface
US5032504A (en) * 1988-10-07 1991-07-16 Eastman Kodak Company Diagnostic test kit and method for determination of chlamydial or gonococcal antigens using a microporous membrane
EP0443191A2 (fr) * 1990-02-23 1991-08-28 Miles Inc. Contrôle d'adéquation de spécimen pour des essais de chlamydias
US5047325A (en) * 1988-10-07 1991-09-10 Eastman Kodak Company Wash solution containing a cationic surfactant and its use in chlamydial and gonococcal determinations
US5047326A (en) * 1988-10-07 1991-09-10 Eastman Kodak Company Immunmological reagent composition and its use in the determination of chlamydial or gonococcal antigens
US5075221A (en) * 1988-10-07 1991-12-24 Eastman Kodak Company Stabilized extraction composition containing a sulfhydryl-containing reducing agent and its use in chlamydial and gonococcal determinations
US5075220A (en) * 1988-10-07 1991-12-24 Eastman Kodak Company Determination of a chlamydial or gonococcal antigen using a positively-charged ionically binding support
US5132205A (en) * 1988-10-07 1992-07-21 Eastman Kodak Company High ph extraction composition and its use to determine a chlamydial, gonococcal or herpes antigen
US5132085A (en) * 1991-02-28 1992-07-21 Eastman Kodak Company Test device with novel control symbolism
US5234817A (en) * 1988-10-07 1993-08-10 Eastman Kodak Company Wash solution containing a cationic surfactant and its use in chlamydial and gonococcal determinations
WO1995029756A1 (fr) * 1994-05-03 1995-11-09 Spectral Diagnostics, Inc. Kit de test medical
EP0763738A1 (fr) * 1995-09-14 1997-03-19 Unipath Limited Dosage pour déterminer Chlamydia dans les échantillons d'urine
WO1999045395A1 (fr) * 1998-03-04 1999-09-10 Universal Healthwatch, Inc. Test de confirmation rapide d'infections microbiennes
USRE41005E1 (en) 1996-11-06 2009-11-24 Sequenom, Inc. Beads bound to a solid support and to nucleic acids

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2035646A1 (fr) * 1990-04-12 1991-10-13 Kollen K. Messenger Dosage immunologique de chlamydia au moyen de la methode demi-sandwich
US7885697B2 (en) 2004-07-13 2011-02-08 Dexcom, Inc. Transcutaneous analyte sensor
US7920906B2 (en) 2005-03-10 2011-04-05 Dexcom, Inc. System and methods for processing analyte sensor data for sensor calibration
US9247900B2 (en) 2004-07-13 2016-02-02 Dexcom, Inc. Analyte sensor
US20070045902A1 (en) 2004-07-13 2007-03-01 Brauker James H Analyte sensor

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4042329A (en) * 1974-12-18 1977-08-16 Becton, Dickinson And Company Method and device for detecting cholesterol
US4338094A (en) * 1979-10-25 1982-07-06 Nasik Elahi Macroencapsulated immunosorbent assay technique
EP0119622A2 (fr) * 1983-03-17 1984-09-26 Fuji Photo Film Co., Ltd. Elément intégral pour réaction biologique et procédé pour sa préparation
EP0173375A1 (fr) * 1984-07-23 1986-03-05 Polaroid Corporation Nouveau produit pour faire les essais et procédé
EP0200381A1 (fr) * 1985-04-04 1986-11-05 Hybritech Incorporated Système à phase solide pour l'utilisation dans des essais du type ligand-récepteur
EP0217403A2 (fr) * 1985-10-04 1987-04-08 Abbott Laboratories Dispositif analytique en phase solide et procédé pour son utilisation
EP0269876A2 (fr) * 1986-11-24 1988-06-08 Abbott Laboratories Dispositif de concentration d'échantillon pour un appareil analytique de phase solide

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4042329A (en) * 1974-12-18 1977-08-16 Becton, Dickinson And Company Method and device for detecting cholesterol
US4338094A (en) * 1979-10-25 1982-07-06 Nasik Elahi Macroencapsulated immunosorbent assay technique
EP0119622A2 (fr) * 1983-03-17 1984-09-26 Fuji Photo Film Co., Ltd. Elément intégral pour réaction biologique et procédé pour sa préparation
EP0173375A1 (fr) * 1984-07-23 1986-03-05 Polaroid Corporation Nouveau produit pour faire les essais et procédé
EP0200381A1 (fr) * 1985-04-04 1986-11-05 Hybritech Incorporated Système à phase solide pour l'utilisation dans des essais du type ligand-récepteur
EP0217403A2 (fr) * 1985-10-04 1987-04-08 Abbott Laboratories Dispositif analytique en phase solide et procédé pour son utilisation
EP0269876A2 (fr) * 1986-11-24 1988-06-08 Abbott Laboratories Dispositif de concentration d'échantillon pour un appareil analytique de phase solide

Cited By (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU616673B2 (en) * 1987-07-14 1991-11-07 Victoria University Of Manchester, The Method for the diagnosis of infections with detection of lipopolysaccharide antigens
WO1989000695A1 (fr) * 1987-07-14 1989-01-26 The Victoria University Of Manchester Procede permettant le diagnostic d'infections par detection d'antigenes de lipopolysaccharide
US4818677A (en) * 1987-12-03 1989-04-04 Monoclonal Antibodies, Inc. Membrane assay using focused sample application
EP0335244A2 (fr) * 1988-03-28 1989-10-04 Abbott Laboratories Dispositif d'analyse en phase solide et procédé pour son utilisation
EP0335244A3 (en) * 1988-03-28 1990-05-30 Abbott Laboratories Solid-phase analytical device and method for using same
US5075220A (en) * 1988-10-07 1991-12-24 Eastman Kodak Company Determination of a chlamydial or gonococcal antigen using a positively-charged ionically binding support
US5132205A (en) * 1988-10-07 1992-07-21 Eastman Kodak Company High ph extraction composition and its use to determine a chlamydial, gonococcal or herpes antigen
US5047325A (en) * 1988-10-07 1991-09-10 Eastman Kodak Company Wash solution containing a cationic surfactant and its use in chlamydial and gonococcal determinations
US5047326A (en) * 1988-10-07 1991-09-10 Eastman Kodak Company Immunmological reagent composition and its use in the determination of chlamydial or gonococcal antigens
US5032504A (en) * 1988-10-07 1991-07-16 Eastman Kodak Company Diagnostic test kit and method for determination of chlamydial or gonococcal antigens using a microporous membrane
US5075221A (en) * 1988-10-07 1991-12-24 Eastman Kodak Company Stabilized extraction composition containing a sulfhydryl-containing reducing agent and its use in chlamydial and gonococcal determinations
US5234817A (en) * 1988-10-07 1993-08-10 Eastman Kodak Company Wash solution containing a cationic surfactant and its use in chlamydial and gonococcal determinations
US5710049A (en) * 1989-06-05 1998-01-20 Janssen Pharmaceutica, N.V. Solid phase assay for use with a physical developer
EP0401913A1 (fr) * 1989-06-05 1990-12-12 Janssen Pharmaceutica N.V. Dosage en phase solide à utiliser avec un développeur physique
EP0402993A2 (fr) * 1989-06-14 1990-12-19 Johnson & Johnson Clinical Diagnostics, Inc. Trousse d'essai diagnostique et procédé pour la détermination de l'antigène chlamydia utilisant une membrane ayant des groupes hydroxyles à la surface
EP0402993A3 (fr) * 1989-06-14 1992-03-18 Johnson & Johnson Clinical Diagnostics, Inc. Trousse d'essai diagnostique et procédé pour la détermination de l'antigène chlamydia utilisant une membrane ayant des groupes hydroxyles à la surface
EP0443191A3 (en) * 1990-02-23 1992-10-21 Molecular Diagnostics, Inc. Specimen adequacy control for chlamydia assays
EP0443191A2 (fr) * 1990-02-23 1991-08-28 Miles Inc. Contrôle d'adéquation de spécimen pour des essais de chlamydias
US5132085A (en) * 1991-02-28 1992-07-21 Eastman Kodak Company Test device with novel control symbolism
WO1995029756A1 (fr) * 1994-05-03 1995-11-09 Spectral Diagnostics, Inc. Kit de test medical
US5658801A (en) * 1994-05-03 1997-08-19 Spectral Diagnostics Inc. Medical test kit
EP0763738A1 (fr) * 1995-09-14 1997-03-19 Unipath Limited Dosage pour déterminer Chlamydia dans les échantillons d'urine
USRE41005E1 (en) 1996-11-06 2009-11-24 Sequenom, Inc. Beads bound to a solid support and to nucleic acids
USRE44693E1 (en) 1996-11-06 2014-01-07 Sequenom, Inc. Beads bound to a solid support and to nucleic acids
WO1999045395A1 (fr) * 1998-03-04 1999-09-10 Universal Healthwatch, Inc. Test de confirmation rapide d'infections microbiennes

Also Published As

Publication number Publication date
DE3786388D1 (de) 1993-08-05
ES2042526T3 (es) 1993-12-16
JPS63198969A (ja) 1988-08-17
DE3786388T2 (de) 1994-01-05
JPH07104354B2 (ja) 1995-11-13
AU605185B2 (en) 1991-01-10
CA1306415C (fr) 1992-08-18
EP0264036A3 (en) 1989-08-09
JP2541793B2 (ja) 1996-10-09
AU7948287A (en) 1988-04-21
ATE91178T1 (de) 1993-07-15
JPH08105898A (ja) 1996-04-23
EP0264036B1 (fr) 1993-06-30

Similar Documents

Publication Publication Date Title
EP0264036B1 (fr) Dispositif analytique et méthode pour la détection de chlamydia trachomatis et neisseria gonorrhoeae
EP0269876B1 (fr) Dispositif de concentration d'échantillon pour un appareil analytique de phase solide
US5185127A (en) Test device including flow control means
EP0335244B1 (fr) Dispositif d'analyse en phase solide et procédé pour son utilisation
EP0217403B1 (fr) Dispositif analytique en phase solide et procédé pour son utilisation
US5160701A (en) Solid-phase analytical device and method for using same
EP0418765A2 (fr) Appareil d'analyse comportant des moyens de contrôle de flux
EP0556202B1 (fr) Analyse de detection amelioree de ligands
AU673907B2 (en) Method and apparatus for immunoassays
CA1272127A (fr) Systeme de dosage ligand-recepteur en phase solide
AU637399B2 (en) Improved solid assay support systems
JPH01244369A (ja) 焦点化した試料の適用による改良された膜アッセイ
EP0186100A2 (fr) Dispositif analytique et méthode pour son emploi
US5942442A (en) Detection of low level analytes in samples using agglutination reaction capillary slide test and apparatus therefor
GB2199946A (en) Diagnostic device,
WO2001024931A1 (fr) Dispositif capillaire de separation de composants non desires d'un echantillon liquide et procede relatif
GB2339904A (en) Membrane carrying assay areas

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE CH DE ES FR GB IT LI NL

PUAL Search report despatched

Free format text: ORIGINAL CODE: 0009013

AK Designated contracting states

Kind code of ref document: A3

Designated state(s): AT BE CH DE ES FR GB IT LI NL

17P Request for examination filed

Effective date: 19900202

17Q First examination report despatched

Effective date: 19910912

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE CH DE ES FR GB IT LI NL

REF Corresponds to:

Ref document number: 91178

Country of ref document: AT

Date of ref document: 19930715

Kind code of ref document: T

REF Corresponds to:

Ref document number: 3786388

Country of ref document: DE

Date of ref document: 19930805

ET Fr: translation filed
K2C2 Correction of patent specification (partial reprint) published

Effective date: 19930630

ITF It: translation for a ep patent filed
REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2042526

Country of ref document: ES

Kind code of ref document: T3

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

26N No opposition filed
NLR4 Nl: receipt of corrected translation in the netherlands language at the initiative of the proprietor of the patent
PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: AT

Payment date: 20010913

Year of fee payment: 15

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20010914

Year of fee payment: 15

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: NL

Payment date: 20010921

Year of fee payment: 15

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 20011005

Year of fee payment: 15

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: ES

Payment date: 20011023

Year of fee payment: 15

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 20011030

Year of fee payment: 15

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: BE

Payment date: 20011113

Year of fee payment: 15

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: CH

Payment date: 20011219

Year of fee payment: 15

REG Reference to a national code

Ref country code: GB

Ref legal event code: IF02

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GB

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20021002

Ref country code: AT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20021002

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: ES

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20021003

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20021031

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20021031

Ref country code: BE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20021031

BERE Be: lapsed

Owner name: *ABBOTT LABORATORIES

Effective date: 20021031

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NL

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20030501

Ref country code: DE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20030501

GBPC Gb: european patent ceased through non-payment of renewal fee

Effective date: 20021002

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20030630

NLV4 Nl: lapsed or anulled due to non-payment of the annual fee

Effective date: 20030501

REG Reference to a national code

Ref country code: FR

Ref legal event code: ST

REG Reference to a national code

Ref country code: ES

Ref legal event code: FD2A

Effective date: 20031112

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES;WARNING: LAPSES OF ITALIAN PATENTS WITH EFFECTIVE DATE BEFORE 2007 MAY HAVE OCCURRED AT ANY TIME BEFORE 2007. THE CORRECT EFFECTIVE DATE MAY BE DIFFERENT FROM THE ONE RECORDED.

Effective date: 20051002